Laboratorios Richmond SACIF 2022 SR
The report highlights Laboratorios Richmond's 2022 performance, focusing on its transformation into biotechnology and the commissioning of the High Potency Production Unit (UPAP). The company successfully fulfilled its Sputnik V vaccine commitments and signed a new agreement with CanSino Biologics to manufacture vaccines locally in Argentina. Key product launches included TRI-ZEVUVIR for HIV and two oncology molecules. Environmentally, the company maintained ISO 14001 certification and reduced energy intensity. Socially, it continued supporting education through the Sadosky Scholarships and the Educational Laboratory Jorge Di Pasquale at UMET.
Company: Laboratorios Richmond SACIF
Sector: Health Care
Country: Argentina
Year: 2022
Type: SR
Pages: 52
Laboratorios Richmond SACIF
Sustainability Report
The report highlights Laboratorios Richmond's 2022 performance, focusing on its transformation into biotechnology and the commissioning of the High Potency Production Unit (UPAP). The company successfully fulfilled its Sputnik V vaccine commitments and signed a new agreement with CanSino Biologics to manufacture vaccines locally in Argentina. Key product launches included TRI-ZEVUVIR for HIV and two oncology molecules. Environmentally, the company maintained ISO 14001 certification and reduced energy intensity. Socially, it continued supporting education through the Sadosky Scholarships and the Educational Laboratory Jorge Di Pasquale at UMET.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Mar 9, 2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Women on Board
Employees